-
First-trimester screening for trisomy 21 using nuchal translucency and nasal bone evaluations in a selected and an unselected population.
Sonek J, Cicero S, Nicolaides K.
Am J Obstet Gynecol 2007;196:19. -
Some thoughts on the true value of ultrasound.
Nicolaides KH.
Ultrasound Obstet Gynecol 2007;30:671-4. -
Discordance in nuchal translucency thickness in the prediction of severe twin-to-twin transfusion syndrome.
Kagan KO, Gazzoni A, Sepulveda-Gonzalez G, Sotiriadis A, Nicolaides KH.
Ultrasound Obstet Gynecol 2007;29:527-32. -
Nuchal translucency and the risk of congenital heart disease.
Hyett J, Sonek J, Nicolaides KH.
Obstet Gynecol 2007;109:1455-6. -
Nuchal translucency measurements for first-trimester screening: The 'price' of inaccuracy.
Evans MI, Van Decruyes H, Nicolaides KH.
Fetal Diagn Ther 2007;22:401-404. -
Glycosaminoglycans and proteoglycans in the skin of aneuploid fetuses with increased nuchal translucency.
von Kaisenberg CS, Prols F, Nicolaides KH, Maass N, Meinhold-Heerlein I, Brand-Saberi B.
Hum Reprod 2003;18:2544-61. -
Delta-NT or NT MoM: which is the most appropriate method for calculating accurate patient-specific risks for trisomy 21 in the first trimester?
Spencer K, Bindra R, Nix AB, Heath V, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:142-8. -
Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience.
Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH.
BJOG 2003;110:281-6. -
Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K, Nicolaides KH.
BJOG 2003;110:276-80. -
Ear length in trisomy 21 fetuses at 11-14 weeks of gestation.
Sacchini C, El-Sheikhah A, Cicero S, Rembouskos G, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:460-3. -
Sonographic markers of fetal aneuploidy: a review.
Cicero S, Sacchini C, Rembouskos G, Nicolaides KH.
Placenta 2003;24:S88-98. -
Integrated ultrasound and biochemical screening for trisomy 21 using fetal nuchal translucency, absent fetal nasal bone, free beta-hCG and PAPP-A at 11 to 14 weeks.
Cicero S, Bindra R, Rembouskos G, Spencer K, Nicolaides KH.
Prenat Diagn 2003;23:306-10. -
Absent nasal bone at 11-14 weeks of gestation and chromosomal defects.
Cicero S, Longo D, Rembouskos G, Sacchini C, Nicolaides KH.
Ultrasound Obstet Gynecol 2003;22:31-5.